FDA’s October ibogaine request is not an approval. Explore its trial-design and safety questions, with public comments due November 20, 2026.

On September 14, FDA will hear public input about training, patient safety, access, and data standards for potential future psychedelic therapies. The hearing is not an ibogaine approval review—but its questions highlight the evidence and safeguards ibogaine research still needs.

H.R. 9559 would create new federal pathways for psychedelic-drug research, Schedule I investigational access, rescheduling review, and Veterans Affairs readiness. Here is what the introduced IBOGAINE Act actually proposes—and why it is not yet law or treatment approval.

Arizona has awarded Barrow Neurological Institute $5 million for a placebo-controlled ibogaine trial in people with chronic traumatic brain injury symptoms. Here is what researchers plan to study, why the design matters, and what the announcement does not yet prove.

A new FDA-allowed study of noribogaine and final federal guidance for psychedelic drug trials mark a meaningful research moment. Here is what changed in 2026, what remains unproven, and why careful clinical evidence still matters.

Noribogaine, a primary metabolite of ibogaine, is drawing new attention in 2026 as researchers explore how ibogaine-related compounds might be studied. Here is what that momentum means, what remains unknown, and why safety data still comes first.

Ibogaine doesn't work like any other addiction treatment. By simultaneously resetting multiple neurotransmitter systems, interrupting withdrawal within hours, and triggering a profound introspective experience, it offers a biological and psychological fresh start that conventional detox cannot replicate.

Ibogaine carries a weight of stigma that has nothing to do with the evidence. It is dismissed as dangerous, unproven, or a last resort for the desperate. Each of these characterizations is wrong — and understanding why matters for patients who deserve accurate information.

Iboga and ibogaine are often used interchangeably, but they are fundamentally different substances with distinct chemical profiles, experiences, and clinical applications. Learn what sets them apart and why the distinction matters for your safety.

Ibogaine is not for everyone — and understanding who it is and is not appropriate for is essential before making any treatment decision. This guide covers the full candidacy picture: who benefits most, who should not consider it, and what the evaluation process involves.

The 2023 Stanford study of ibogaine in combat veterans produced results that stunned the psychiatric research community. PTSD severity dropped 88 percent. Depression dropped 87 percent. What does this mean for the future of mental health treatment — and for patients who have run out of options?

Most people discover ibogaine through its reputation as an addiction interrupter. But the compound's neurobiological reach extends far beyond substance dependence — into depression, PTSD, trauma, anxiety, and executive burnout. Here's what the emerging science says.

Not all ibogaine clinics are created equal. This guide covers the non-negotiable medical safety standards, red flags to avoid, and the right questions to ask before trusting any facility with your care.

Ibogaine treatment in Mexico typically ranges from $5,000 to $12,000 — but what separates a safe, effective program from a dangerous one isn't always the price tag. Here's what you actually need to know before booking.